| Literature DB >> 25487710 |
J Zeyland1, D Lipiński, R Słomski.
Abstract
Pigs as a source of grafts for xenotransplantation can help to overcome the rapidly growing shortage of human donors. However, in the case of pig-to-human transplantation, the antibody-xenoantigen complexes lead to the complement activation and immediate hyperacute rejection. Methods eliminating hyperacute rejection (HAR) include α1,3-galactosyltransferase (GGTA1) inactivation, regulation of the complement system and modification of the oligosaccharide structure of surface proteins. The humoral immune response control and reduction of the risk of coagulation disorders are the priority tasks in attempts to overcome acute humoral xenograft rejection that may occur after the elimination of HAR. The primary targets for research are connected with the identification of obstacles and development of strategies to tackle them. Because of the magnitude of factors involved in the immune, genetic engineers face a serious problem of producing multitransgenic animals in the shortest possible time.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25487710 PMCID: PMC4412840 DOI: 10.1007/s13353-014-0261-6
Source DB: PubMed Journal: J Appl Genet ISSN: 1234-1983 Impact factor: 3.240
Pig genetic modifications for xenotransplantation
| Introduced/inactivated gene | Expected effect |
|---|---|
| p GGTA1 | Inactivation/ prevents HAR |
| h CD55, CD46, CD59 | Expression/ prevents HAR |
| h HT | Expression/ prevents HAR |
| h GLA | Expression/ prevents HAR |
| p CMAH | Inactivation/ reduces xenoantigenicity |
| HLA-E/h β2-microglobulin | Expression/ prevents rejection assisted by NK cells |
| p ULBP1 | Inactivation/ prevents rejection assisted by NK cells |
| h CD47 | Expression/ prevents rejection assisted by macrophages |
| h CD39 | Expression/ prevents thrombosis |
| h TM, TFPI | Expression/ prevents delayed xenograft rejection |
| p CTLA4-Ig | Expression/ prevents the T-cell-mediated response |
| LEA29Y | Expression/ prevents activation of T-cells |
| h CIITA-DN | Expression/ prevents human cellular immune response |
| h TRAIL | Expression/ prevents cellular immune response |
| PERV siRNA | Expression/ prevents activation of PERV |
| h GnT-III | Expression/ reduces xenoantigenicity |
| h TNFRI-Fc | Expression/ prevents hTNF-α-mediated inflammation and apoptosis |
| h A20 | Expression/ prevents acute vascular rejection |
| h HO-1 | Expression/ anti-oxidative, anti-apoptotic, and anti-inflammatory effect |
p – porcine, h – human, ULBP1 (UL16 binding protein 1), HLA (human leukocyte antigen), CTLA4Ig (cytoxic T-lymphocyte associated antigen4-immunoglobulin); TNFRI-Fc (tumor necrosis factor-alpha receptor I-Fc); HO-1 (heme oxygenase-1); CIITA-DN (dominant-negative mutant class II transactivator), GnT-III (N-acetylglucosaminyltransferase III), A20 (tumor necrosis factor-alpha–induced protein 3)